Circular RNA FOXO3 accelerates glycolysis and improves cisplatin sensitivity in lung cancer cells via the miR-543/Foxo3 axis

YANNI ZHANG1, PAN GE2, DANGXIA ZHOU2, RONG XING3 and LIZHI BAI4

1Department of Emergency Respiratory, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001; 2Department of Pathology and Pathophysiology, School of Medicine, Xi'an Jiaotong University, Xian, Shanxi 710049; 3Department of Pathology and Pathophysiology, Dalian Medical University, Dalian, Liaoning 116023; 4Department of Thoracic Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116001, P.R. China

Received October 29, 2020; Accepted September 2, 2021

DOl: 10.3892/ol.2021.13100

Correspondence to: Dr Lizhi Bai, Department of Thoracic Surgery, Affiliated Zhongshan Hospital of Dalian University, 6 Jiefang Road, Zhongshan, Dalian, Liaoning 116001, P.R. China
E-mail: blz_res@163.com

Abbreviations: NSCLC, non-small cell lung cancer; circRNA, circular RNA; DDP, cisplatin; ceRNA, competing endogenous RNA

Key words: NSCLC, DDP, resistance, circRNA, microRNA-543

Abstract. Non-small cell lung cancer (NSCLC) is the most common cause of cancer-associated mortality worldwide. Our previous study revealed that circular RNA (circRNA)-FOXO3 is highly expressed in lung cancer and inhibits cell proliferation. However, to the best of our knowledge, at present, no study has focused on the specific mechanism of circRNA-FOXO3 in drug resistance. Therefore, the present study aimed to provide novel perspectives on the role of circRNA-FOXO3 in cisplatin (DDP) resistance in NSCLC. A Cell Counting Kit-8 assay was used to determine the viability of cells overexpressed with circRNA-FOXO3 and under DDP treatment. Glycolysis was analyzed by measuring glucose consumption and lactate production. The interaction of circRNA-FOXO3, microRNA 543 (miR-543) and Foxo3 was confirmed using a dual-luciferase reporter assay. It was revealed that circRNA-FOXO3 improved cell sensitivity to DDP and repressed glycolysis in DDP-sensitive and DDP-resistant NSCLC cells. Bioinformatics analysis, luciferase reporter assays, quantitative PCR and RNA pull-down assays were employed to verify the binding of circRNA-FOXO3 to miR-543. Functionally, inhibition of miR-543 could sensitize NSCLC cells to DDP, and overexpression of miR-543 at least partially abolished the circRNA-FOXO3-induced decrease in chemoresistance. Furthermore, it was revealed that Foxo3 was a direct target of miR-543. Notably, the inhibitory action of miR-543 silencing on DDP resistance and glycolysis was reversed by overexpression of Foxo3 in DDP-sensitive and DDP-resistant NSCLC cells. In conclusion, the present study demonstrated that circRNA-FOXO3 promoted DDP sensitivity in NSCLC cells by regulating the miR-543/Foxo3 axis-mediated glycolysis balance. The present findings may provide novel perspectives for the treatment of patients with NSCLC resistant to DDP.

Introduction

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases worldwide, and the 5-year overall survival rate is only ~15% in 2019 (1,2). At present, supplementary therapy is used to treat patients with NSCLC following surgery, and cisplatin (DDP) is widely considered to be a first-line chemotherapeutic agent for such patients (3,4). Although DDP has broad-spectrum anticancer activity, its usefulness is limited by the high incidence of chemoresistance (5). Despite previous efforts, the mechanisms underlying DDP resistance in NSCLC are not well understood. Therefore, there is an urgent need to elucidate these mechanisms.

Circular RNAs (circRNAs) are covalently closed RNA molecules generated by the back-splicing process (6). They are abundant in the human body and have multiple biological functions (7), including acting as ‘sponges’ for microRNAs (miRNA/miRs), thus regulating gene expression at the post-transcriptional level (8). Aberrant expression of circRNAs is reportedly associated with cancer progression, and they have also been noted to act in the regulation of NSCLC pathogenesis (9,10). For example, hsa_circ_0076305 is highly expressed in NSCLC cells and tissues, and knockdown of circ_0076305 increases the sensitivity of NSCLC cells to DDP by modulating the miR-296-5p/STAT3 axis (11). In addition, Wu et al (12) identified that circ-ATP binding cassette subfamily B member 10 depletion suppresses lung cancer progression and sensitizes lung cancer cells to DDP. Our previous study revealed that circRNA-FOXO3 could act as a tumor suppressor in NSCLC (13). However, to the best of our knowledge, the role of circRNA-FOXO3 in DDP resistance remains unclear.

The regulation of tumor metabolism as a therapeutic strategy holds promise for all types of cancer, including NSCLC (14). Aberrant tumor glucose metabolism and the increased rates of glycolysis in tumors are associated with
intrinsic/acquired resistance to routinely used anticancer drugs (15). The present study was designed to determine the effects of circRNA-FOXO3 on NSCLC glycolysis and DDP resistance. The results of the present study revealed the molecular mechanisms of circRNA-FOXO3 in NSCLC glycolysis via miR-543/Foxo3, suggesting the underlying pathogenesis for NSCLC and providing a therapeutic strategy for precise treatment.

Materials and methods

Tissue collection. NSCLC tissue samples and adjacent non-cancerous tissues were collected from 45 patients (25 men and 20 women; age range, 35-77 years; median age, 56 years) who received lobectomy at the Affiliated Zhongshan Hospital of Dalian University between January 2017 and September 2018. Paired adjacent normal tissues were also collected (2 cm from the lesion). All patients had pathologically confirmed disease, and the samples were collected before the initiation of chemotherapy or radiation therapy. The following patients were excluded: i) Patients with other pulmonary diseases, or severe hepatic or renal dysfunction; ii) patients with other comorbid malignant tumors; and iii) patients with immune system disorders. Tissue samples were obtained during surgery, snap-frozen with liquid nitrogen and stored at -80°C. The use of clinical samples was approved by the Research Scientific Ethics Committee of the Affiliated Zhongshan Hospital of Dalian University (Dalian, China) and written informed consent was obtained from all participants.

Cell culture. The NSCLC cell lines (NCI-H1650, NCI-H1299, A549 and SK-MES-1, (all previously obtained from the American Type Culture Collection) were maintained at the Affiliated Zhongshan Hospital of Dalian University as previously described (13). The DDP-resistant H1975 lung cancer cell line was established according to a previously described method (16). Specifically, H1975/DDP cells were obtained by exposing H1975 cells to stepwise-increasing concentrations of DDP (cat. no. 479306; Sigma-Aldrich; Merck KGaA). Cells were initially supplemented with DDP at 2 µM and after stable growth for 2 weeks, its concentration was increased to 4 µM for another 2 weeks of incubation. The dose of DDP was steadily increased until the cells reached a stable growth phase with the medium containing 50 µM DDP, thus generating a DDP-resistant cell line, H1975/DDP cells. The cells were maintained in RPMI medium (Sigma-Aldrich; Merck KGaA) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in an incubator at 37°C with 5% CO₂.

Cell transduction. The circRNA-FOXO3 cDNA (5'-AAA AGAAGCTAGGACGTATCTAA-3'; 10 nM) was cloned into pcDNA3.1 plasmid (DNM3, V87020; Thermo Fisher Scientific, Inc.) and empty pcDNA3.1 plasmid (Thermo Fisher Scientific, Inc.) containing pCDNA3.1 plasmid (Thermo Fisher Scientific, Inc.) containing control oligonucleotides (designed as mock group, 5'-AGGGATCTCCGTAGGACCCTG-3'; 10 nM) were assembled by Shanghai GenePharma Co., Ltd. Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection according to the manufacturer’s instructions. The has-miR-543 mimic, anti-miR-543 and negative controls (miR-NC and anti-miR-NC) were designed and constructed by Guangzhou RiboBio Co., Ltd. Cells were seeded into a 96-well plate, and then transfected with the miR-543 mimic, anti-miR-543 and negative controls at a concentration of 80 nmol/ml using Lipofectamine 3000® at 37°C for 24 h. Transfected cells were cultured in 6-well plates containing medium, which was refreshed every 12 h.

Microarray analysis A549 cells were transfected with circRNA-FOXO3 or control plasmid and cells were then incubated at 37°C for 24 h. Total RNA was extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and then purified using the RNasey Mini kit (Qiagen, Inc.), amplified and labeled using the Quick Amp Labeling kit, One-Color (Agilent Technologies, Inc.), according to the manufacturer's instructions. An equal amount of labeled cRNA from each sample was hybridized using the Agilent Gene Expression Hybridization kit (Agilent Technologies, Inc.), followed by image acquisition on the Agilent DNA Microarray Scanner (G5761A) and data analysis using the Feature Extraction software (version 12.0.3.1; Agilent Technologies, Inc.).

Cell Counting Kit-8 (CCK-8) cell viability assay. Cell viability was assessed using a CCK-8 assay. A549 cells or H1975/DDP cells were transferred into 96-well plates at a density of at 5x10⁵ cells/well and maintained for 24 h. After transfection with indicated RNA oligonucleotides or vectors, cells were exposed to different doses of DDP (0-64 µM; Sigma-Aldrich; Merck KGaA) and kept for 24 h. CCK-8 (10 µl/well; MedChemExpress) was then added to the wells and cells were incubated in the dark at 37°C for 2 h. The optical density value at 450 nm was determined on a microplate reader (Bio-Rad Laboratories, Inc.).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA from lung tissues or cells was extracted using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The purity and concentration of the various RNA samples were measured using a NanoDrop ND-2000 (Thermo Fisher Scientific, Inc.) by measuring the absorbance at 260 and 280 nm. Synthesis of cDNA was performed using a SuperScript VILO cDNA Synthesis kit (Invitrogen; Thermo Fisher Scientific, Inc.) in a thermal cycler using the following primers: 5'-AACAGAAGCTTGGACGTATCTAA-3' for miR-543, and 5'-AACAGAAGCTTGGACGTATCTAA-3' for U6. The PCR conditions were as follows: 95°C for 10 min; followed by 40 cycles of 95°C for 10 s, 55°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 5 min. The expression levels of miR-543 were normalized to the U6 levels using the 2-AΔΔCq method (17). The following primer sets were used: circRNA-FOXO3 forward, 5'-GTGGGGGAAAC TTCACCTTGTCAGTAA-3' and reverse, 5'-GGGTGTGATG ATCCACCAAGACTCCTCT-3'; miR-543 forward, 5'-AAA CATTCCG-3' and reverse, 5'-AAGAAGTGAC-3'; Foxo3 forward, 5'-GCCAGAGCTCTTGTGGATCATCA-3' and reverse, 5'-TTGGGTGTCAGCCACCTTGAGAG-3'; U6 forward, 5'-CTCTCGCAAGAGTTCG-3' and reverse, 5'-GTCGAGGGTGTCAGGT-3'; and GAPDH forward, 5'-GAAGGTT GAAGTCGGAGTC-3' and reverse, 5'-GAAGATGTTGAT GGGATTTC-3'.
Glucose and lactate measurements. After transfection for 48 h, the cultured cells were digested with 0.25% trypsin and centrifuged at 960 x g for 5 min at room temperature to obtain the supernatant. The glucose uptake and lactate production in the supernatant were measured using glucose uptake colorimetric assay kit (cat. no. MAK083, Sigma-Aldrich; Merck KGaA) and a Lactic Acid assay kit (cat. no. BC2230; Nanjing KeyGen Biotech Co., Ltd.), respectively, according to the manufacturer's protocol.

Bioinformatics analysis. The StarBase 3.0 database (http://starbase.sysu.edu.cn) was used to determine the molecular mechanism by which circRNA-FOXO3 regulates miR-543.

Luciferase reporter assay. Luciferase reporter assay pGL3 Luciferase Reporter Vector (Promega BioVision; Promega Corporation) was used to construct the Foxo3 vector. A549 cells were transfected with Foxo3 vector (5'-TCAGGCACCA ATTCTAAGCG-3') and miR-543 mimic (miR-543 group: 5'-AAGUGCCCGGUUUUUCG-3') or Foxo3 vector and NC miRNA (miR-NC: 5'-UUUGACUCACAAAAAAGUACUG-3'). The wild-type (WT) Foxo3 sequence containing the miR-543-binding sequence and the mutant (MUT) Foxo3 sequence were cloned into the pmirGLO dual luciferase miRNA target expression vector in strict accordance with the provided instructions of the luciferase detection kit (Promega Corporation). Cells were harvested at 48 h post-transfection, and a Dual-Luciferase Reporter Assay System (Promega Corporation) was used to measure luciferase activity. Renilla luciferase activity was used for normalization.

RNA-pulldown assay. An RNA pull-down assay was conducted to verify the relationship between circRNA-FOXO3 and miR-543 using the Pierce Magnetic RNA-Protein Pull-Down kit (BersinBio; http://www.share-bio.com/product/943.html). Bio-circRNA-FOXO3 (or Bio-miR-543) and Bio-NC (Guangzhou RiboBio Co., Ltd.) were transcribed by the Biotin RNA Labeling Mix (Roche Diagnostics) and T7 RNA polymerase (Promega Corporation), and A549 cells were transfected with 50 nM of above Biotin-labeled RNA, using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were fixed with 1% formaldehyde and lysed with the RIPA lysis buffer (BersinBio). A total of 1 ml of lysates were subsequently centrifuged at 10,000 x g for 10 min at 4°C. The biotin-coupled RNA complex was pulled down using Streptavidin-Dyna beads M-280 (cat. no. 11206D; Invitrogen; Thermo Fisher Scientific, Inc.) and Proteinase K (Sigma-Aldrich; Merck KGaA) was added and incubated with the supernatants overnight at 4°C to isolate the RNA overnight at 4°C. The bead-probe-RNA mixture was then incubated with the supernatants overnight at 4°C to isolate the RNA overnight at 4°C. Proteinase K (Sigma-Aldrich; Merck KGaA) and a Lactic Acid assay kit (cat. no. BC2230; Nanjing KeyGen Biotech Co., Ltd.), respectively, according to the manufacturer's protocol.

Statistical analysis. Data were obtained from at least three independent experiments and are presented as the mean ± standard deviation. Data were analyzed using GraphPad Prism 8 software (GraphPad Software, Inc.). Differences between pairs of groups were evaluated using unpaired two-tailed Student's t-tests, with the exception that the comparison of circRNA-FOXO3, miR-543 or Foxo3 miRNA levels between lung cancer tissues and adjacent normal tissues was performed using paired Student's t-tests. One-way ANOVA with a subsequent Bonferroni test was performed to determine statistically significant differences among multiple groups. Spearman's correlation analysis was used to assess the correlation between miR-543 and circRNA-FOXO3 or Foxo3.

Results

Glycolysis inhibition and higher DDP sensitivity in NSCLC cells exposed to circRNA-FOXO3. Our previous study revealed that circRNA-FOXO3 acts as a tumor suppressor in lung cancer via the Foxo3 axis (13). In the present study, circRNA-FOXO3 was overexpressed in A549 cells and H1975/DDP cells to investigate its effects on DDP resistance and its underlying mechanism (Fig. 1A). As shown in Fig. 1B, NSCLC cell viability gradually decreased as the concentration of DDP increased. The IC_{50} (17.32 µM) of mock-transfected A549 cells was higher than that of cells transfected with circRNA-FOXO3 (IC_{50}, 5.75 µM). Subsequently, the present study investigated the effect of circRNA-FOXO3 on the glycolytic metabolism in NSCLC cells. The results demonstrated that overexpression of circRNA-FOXO3 was associated with significantly lower glucose consumption and lactate production (Fig. 1C and D). Furthermore, a DDP-resistant lung cancer cell line (H1975/DDP) was established by continuously exposing H1975 cells to a gradually increasing dose of DDP. The IC_{50} of H1975/DDP cells was significantly higher than that of H1975 parental cells (29.99 vs. 12.22 µM; Fig. 1E). Notably, circRNA-FOXO3 expression was lower in H1975/DDP cells than in H1975 parental cells (Fig. 1F). As was shown in Fig. 1G, the sensitivity of lung cancer cells to DDP was significantly increased in the mock group (14). Overall, these data suggested that circRNA-FOXO3 enhanced the sensitivity of lung cancer cells to DDP via regulation of the glycolytic metabolism.

Western blotting. The cultured cells were collected and lysed in RIPA lysis buffer (Beijing Solarbio Science & Technology Co., Ltd.) to obtain total protein. After protein quantification using a bicinchoninic acid kit (Beyotime Institute of Biotechnology), protein (30 µg) was subjected to 12% SDS-PAGE. Separated proteins were then transferred onto polyvinylidene fluoride membranes, which were blocked with 5% non-fat milk at room temperature for 1 h, followed by incubation with anti-human Foxo3 antibody (cat. no. sc-34894; 1:1,000; Santa Cruz Biotechnology, Inc.) or β-actin antibody (cat. no. sc-47778; 1:1,000; Santa Cruz Biotechnology, Inc.) at 4°C overnight. Subsequently, the membranes were incubated with horseradish peroxidase-labeled goat anti-rabbit secondary antibody (cat. no. A0208, 1:1,000; Beyotime Institute of Biotechnology) at room temperature for 1 h. Protein bands were visualized using SuperSignal™ West Pico PLUS (cat. no. 34580; Thermo Fisher Scientific, Inc.) and protein quantification was performed using Quantity One software version 4.6.2 (Bio-Rad Laboratories, Inc.).
Negative association between miR-543 and both lung cancer and DDP resistance. Given that circRNAs can function as competing endogenous RNAs (ceRNAs) in relation to miRNAs, a microRNA array was used to determine the miRNA expression profiles of A549 cells and the data were submitted to the Gene Expression Omnibus database (dataset accession no. GSE182576). In total, 87 upregulated miRNAs and 212 downregulated miRNAs were identified in A549 cells with or without circRNA-FOXO3 overexpression, and a heatmap of the top 50 upregulated and 50 downregulated miRNAs is shown in Fig. 2A. Putative binding sites of circRNA-FOXO3 with Foxo3 were predicted using StarBase 3.0. Among the miRNAs, 32 targeted one or more of these putative binding sites (Fig. 2B). Notably, six miRNAs, of which only one (miR-543) was upregulated, were identified in both the microarray and StarBase results (Fig. 2C). The 3'-untranslated region (UTR) of circRNA-FOXO3 contained a putative miR-543 binding sequence region (Fig. 2D). To examine whether circRNA-FOXO3 was the target of miR-543, miR-543 mimics or miR-NC were transfected into A549 cells. The cells containing miR-543 mimics exhibited significantly higher miR-543 expression (Fig. 2E). Subsequently, dual-luciferase assays were performed in both of these cell lines to validate the regulation of circRNA-FOXO3 by miR-543, and following co-transfection with circRNA-FOXO3 and miR-543, the luciferase activity of the wild-type circRNA-FOXO3 reporter was attenuated (Fig. 2F). Furthermore, an RNA pull-down assay demonstrated that circRNA-FOXO3 interacted directly with miR-543. miR-543 was enriched in the circRNA-FOXO3 probe group compared with the levels in the control group (Fig. 2G). As expected, overexpression of miR-543 partly reversed the higher circRNA-FOXO3 expression (Fig. 2H).

Regulation of chemoresistance and glycolysis by circRNA-FOXO3/miR-543 in lung cancer cells. The results in Fig. 3A demonstrated that the expression levels of circRNA-FOXO3 were significantly downregulated in NSCLC tissues compared with in normal lung tissues. Additionally, the expression levels of miR-543 were markedly upregulated in NSCLC tissues compared with in the corresponding normal tissues (Fig. 3B). Correlation analysis confirmed that circRNA-FOXO3 expression was negatively correlated with miR-543 expression in NSCLC tissues (Fig. 3C). In addition, it was demonstrated that miR-543 expression levels were higher in A549 cells than in normal bronchial epithelial cells of the 16-HBE cell line (Fig. 3D). Furthermore, miR-543 expression was found to be upregulated in H1975/DDP cells compared with in H1975 parental cells (Fig. 3E). Subsequently, miR-543 was upregulated by transfection with miR-543 mimics (Fig. 3F) and downregulated by transfection with anti-miR-543 (Fig. 3G) in H1975/DDP cells. Next, the CCK-8 cell viability assay revealed that inhibition of miR-543 significantly sensitized lung cancer cells to DDP (Fig. 3H). However, overexpression of miR-543 had no effect on the resistance of H1975/DDP cells, as indicated by cell viability assay (Fig. 3I). Subsequently, the present study investigated the role of the circRNA-FOXO3/miR-543 axis in chemoresistance in lung cancer cells. Overexpression of circRNA-FOXO3 reduced lactate production but overexpression of miR-543 reversed this effect (Fig. 4A). At the same time, circRNA-FOXO3 reduced
glucose consumption, whereas miR-543 effectively reversed this effect in A549 cells (Fig. 4B). Furthermore, the results in Fig. 4C demonstrated that A549 cells co-transfected with circRNA-FOXO3 and miR-543 were more viable than the cells treated with circRNA-FOXO3 and miR-NC (IC$_{50}$, 12.74 vs. 3.33 µM). In H1975/DDP cells, circRNA-FOXO3 caused lower glucose consumption (Fig. 4D) and lactate production (Fig. 4E), and higher sensitivity to DDP (Fig. 4F); however, miR-543 mimics reversed the effects of circRNA-FOXO3. Overall, these results indicated that circRNA-FOXO3 regulated chemoresistance and glycolysis in lung cancer cells by sponging miR-543.

Foxo3 is a direct target of miR-543 in lung cancer. Our previous study demonstrated that circRNA-FOXO3 regulates Foxo3 expression via a ceRNA mechanism (13). The present study investigated whether miR-543 regulates Foxo3 expression. By searching the StarBase database, it was observed that binding sites between miR-543 and Foxo3 were proposed (Fig. 5A). It was revealed that Foxo3 mRNA expression was significantly downregulated in lung cancer tumor tissues compared with in the equivalent normal tissues (Fig. 5B). A negative correlation was also observed between miR-543 expression and Foxo3 mRNA expression in lung cancer tissues (Fig. 5C). Using a luciferase reporter assay, it was revealed that miR-543 could interact directly with the 3'-UTR of Foxo3 mRNA. The miR-543 mimics significantly inhibited luciferase activity in the wild-type reporter for Foxo3, whereas they did not inhibit the luciferase activity of the reporter vector containing the mutant binding sites for Foxo3 in A549 cells (Fig. 5D). Furthermore, western blot analysis demonstrated that overexpression of miR-543 significantly inhibited Foxo3 protein expression, whereas knockdown of miR-543 increased Foxo3 protein expression (Fig. 5E and F). These results indicated that Foxo3 was one of the targets of miR-543 in lung cancer.

Restoration of Foxo3 reverses the effects of miR-543 silencing on glycolysis and DDP resistance. Subsequently, the present study
investigated whether miR-543 affected drug resistance in lung cancer by regulating Foxo3. As shown in Fig. 6A, overexpression of Foxo3 was achieved by transfection with a Foxo3 plasmid, the efficiency of which was validated by western blot analysis in both A549 and H1975/DDP cells. miR-543 was then downregulated in A549 cells by transfection with anti-miR-543 (Fig. 6B). Co-transfection of anti-miR-543 and Foxo3 restored the glucose consumption suppressed by miR-543 in A549 cells (Fig. 6C). The present study also revealed that co-transfection of anti-miR-543 and Foxo3 overexpression plasmid increased lactate production compared with the levels in cells in which miR-543 had been silenced (Fig. 6D). The results of the subsequent CCK-8 assay demonstrated that cells overexpressing Foxo3 were less sensitive to DDP than cells transfected with anti-miR-543 in A549 cells (Fig. 6E). Notably, the present study further validated the effects of Foxo3 in H1975/DDP cells. Knocking down miR-543 reduced glucose consumption (Fig. 6F) and lactate production (Fig. 6G), whereas overexpression of Foxo3 reversed the effects of inhibition of miR-543. H1975/DDP cells displayed increased sensitivity to DDP following inhibition of miR-543; however, this sensitization was overridden by Foxo3 rescue (Fig. 6H). Collectively, the aforementioned results indicated that miR-543 suppressed glycolysis and DDP resistance by directly targeting Foxo3 in lung cancer cells.

Figure 3. Association between circRNA-FOXO3 and miR-543 in NSCLC. (A) RT-qPCR analysis of circRNA-FOXO3 in NSCLC tissues and corresponding normal tissues. (B) Relative expression levels of miR-543 in NSCLC tissues and non-tumor tissues. (C) A negative correlation between circRNA-FOXO3 and miR-543 expression in specimens from patients with NSCLC was identified using Spearman’s correlation analysis. (D) Expression levels of miR-543 in 16HBE cells and NSCLC cell lines (NCI-H1250, NCI-H1299, A549 and SK-MES-1) were determined by RT-qPCR. (E) Relative expression levels of miR-543 in H1975 and H1975/DDP cells. (F) Relative expression levels of miR-543 in H1975/DDP cells transfected with miR-543 or miR-NC. (G) Relative expression of miR-543 in H1975/DDP cells transfected with anti-miR-543 mimics or anti-miR-NC. Cell proliferation following treatment with different concentrations of DDP in H1975/DDP cells transfected with (H) anti-miR-543 or anti-miR-NC, or (I) miR-543 mimics or miR-NC. *p<0.05. circRNA, circular RNA; DDP, cisplatin; miR/miRNA, microRNA; NC, negative control; NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative PCR.
Numerous studies have demonstrated that circRNAs are involved in NSCLC tumorigenesis. Yin et al (18) identified that downregulation of double homeobox A pseudogene 8 could suppress cell proliferation and glycolysis by regulating the miR-409-3p/hexokinase 2/lactate dehydrogenase A axis. Wang et al found hsa_circ_0008305 inhibited transforming growth factor-β-induced epithelial-mesenchymal transition and metastasis of NSCLC cells by controlling transcriptional intermediary factor 1γ (19). However, our understanding of how circRNAs function in drug resistance in NSCLC is limited. Guo et al (20) found that circ_0011292 knockdown could suppress NSCLC progression and enhance paclitaxel sensitivity by regulating the miR-379-5p/tripartite motif containing 65 axis. Knocking down circ Rac GTPase activating protein 1 has also been reported to markedly inhibit tumor growth and enhance the sensitivity of NSCLC cells to gefitinib (21). In terms of DDP resistance, Song et al (22) were the first to report circRNA function in drug resistance in NSCLC. Subsequently, Zhao et al (23) demonstrated a novel circRNA in the CDR1 antisense RNA/miR-641/homeobox protein Hox-A9 pathway, which regulates stemness and DDP chemoresistance in NSCLC. Consistent with this, the present results indicated that circRNA-FOXO3 could increase the sensitivity of lung cancer cells to DDP and inhibit glycolysis by regulating the miR-543-Foxo3 axis.

Glycolysis is an important process in tumor cells, providing the main source of energy for rapid tumor expansion (24). Previous studies have demonstrated that circRNAs can regulate glycolysis in cancer cells. For example, circ_0000140 has been found to inhibit the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma by targeting the miR-409-3p/hexokinase 2/lactate dehydrogenase A axis (25). Notably, circRNA-AKT3 has been found to promote DDP resistance in NSCLC cells by regulating the miR-516b-5p/STAT3 axis-mediated glycolysis balance (26). Our previous study demonstrated that circRNA-FOXO3 inhibits the proliferation, migration and invasiveness of NSCLC cells (13). The present study further assessed the role of circRNA-FOXO3 in drug resistance. It was revealed that circRNA-FOXO3 could increase the sensitivity of NSCLC cells to DDP, as well as inhibit glycolysis. As circRNAs have ceRNA functionality, the miRNAs targeted by circRNA-FOXO3 were screened using a miRNA microarray and extracted from the Starbase datasets. Finally, miR-543 was predicted to target the circRNA-FOXO3 3′-UTR. Luciferase reporter, RNA-pulldown, and RT-qPCR assays demonstrated the interaction between circRNA-FOXO3 and miR-543. At present, a role for miR-543 has been revealed in several types of malignant tumor (27), although its specific functions in NSCLC remain poorly understood (28). A recent study has suggested that miR-543 overexpression promotes cell proliferation and angiogenesis by targeting metastasis-associated protein 1 in NSCLC cells (29). In terms of drug resistance in cancer,
Figure 5. Foxo3 is a target of miR-543 in NSCLC cells. (A) Online bioinformatics prediction tools revealed the binding sequences of miR-543 and the Foxo3 mRNA 3′-untranslated region. (B) Relative expression levels of Foxo3 in NSCLC tissues and non-tumor tissues. (C) Spearman's correlation analysis was used to reveal the negative correlation between Foxo3 and miR-543 expression in NSCLC tissues. (D) Luciferase activity of the Foxo3 vector in A549 cells co-transfected with miR-543 mimics or miR-NC. (E and F) Western blot analysis revealed the relative protein expression levels of Foxo3 in A549 cells transfected with anti-miR-543, anti-miR-NC, miR-543 mimics or miR-NC. *P<0.05. miR/miRNA, microRNA; NC, negative control; NSCLC, non-small cell lung cancer.

Figure 6. Foxo3 overexpression reverses the effects of miR-543 silencing on glycolysis and cisplatin resistance. (A) Western blot analysis revealed the relative protein expression levels of Foxo3 in A549 and H1975/DDP cells transfected with Foxo3 or negative control vector. (B) Relative expression levels of miR-543 in A549 cells transfected with anti-miR-543 or anti-miR-NC. (C) Glucose consumption was determined in A549 cells transfected with Foxo3 vectors and/or anti-miR-543. (F) Relative glucose consumption and (G) lactate production of H1975/DDP cells transfected with Foxo3 vectors and/or anti-miR-543. *P<0.05. CCK-8, Cell Counting Kit-8; DDP, cisplatin; miR/miRNA, microRNA; NC, negative control.
miR‑543 has been found to enhance resistance to 5‑fluorouracil by regulating the PTEN/PI3K/AKT signaling pathway in colorectal cancer cells (30). In addition, a recent study revealed that prostate cancer‑associated transcript 6 facilitates the proliferation and metastasis of cervical cancer cells, and their resistance to DDP, via the miR‑543/zinc finger E‑box binding homeobox 1 axis (31). To the best of our knowledge, the present study was the first to reveal that miR‑543 is involved in DDP chemoresistance in NSCLC. Inhibition of miR‑543 significantly increased the sensitivity of NSCLC cells to DDP.

It was revealed that circRNA‑FOXO3 acted as a sponge for miR‑543 and targeted the 3'‑UTR of Foxo3 mRNA, thereby revealing the circRNA‑FOXO3/miR‑543/Foxo3 axis. Because the target effector of circRNA‑FOXO3 is Foxo3, it was hypothesized that circRNA‑FOXO3 regulates glycolysis by regulating Foxo3. A previous study has demonstrated that knockdown of Foxo3 is sufficient to induce apoptosis resistance in conjunction with elevated glycolysis (32). Activation of Foxo3 is compensated for by increased glycolysis and reduced apoptosis (33,34). Consistently, in the present study, overexpression of Foxo3 partially reversed the effects of miR‑543 inhibition on glycolysis and DDP resistance in NSCLC cells. These data support our conclusion that circRNA‑FOXO3 overexpression regulates glycolysis and thus sensitizes NSCLC cells to DDP by activating Foxo3.

The present study had some limitations that should be mentioned. Firstly, the number of samples from patients with NSCLC, which were used to analyze the association between the levels of circRNA‑FOXO3 and miR‑543, was small. Further studies involving more patients are required to further investigate the clinical significance of circRNA‑FOXO3. Secondly, the mechanism study was carried out in two specific cell lines: DDP‑sensitive A549 cells and DDP‑resistant H1975/DDP cells. Further studies on other cell lines should be conducted. Finally, the methods were limited, in that the potential mechanism underlying the involvement of circRNA‑FOXO3 in the chemoresistance of NSCLC cells was demonstrated by an in vitro assay only, and an in vivo xenograft tumor model will be required to fully explore the effect of the circRNA‑FOXO3/miR‑543/Foxo3 axis on the tumor growth and chemoresistance of NSCLC cells in vivo.

In summary, the present study demonstrated that circRNA‑FOXO3 interacted with miR‑543/Foxo3 to increase the sensitivity of NSCLC cells to DDP. The circRNA‑FOXO3/miR‑543/Foxo3 axis may provide a novel therapeutic approach for combating drug resistance during NSCLC treatment.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National High Technology Research and Development Program (‘863 Program) of China (grant no. 2015AA020409) and the Project of Liaoning Province Education Department (grant no. L2014358).

Availability of data and materials

All data generated or analyzed during this study are included in this published article. The microarray dataset generated and/or analyzed during the current study are available in the Gene Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE182576; accession no. GSE182576).

Authors' contributions

LB and PG designed the experiments, supervised the research and reviewed the manuscript. YZ, DZ and RX performed the experiments and analyzed data. YZ and LB confirmed the authenticity of all the raw data. YZ, DZ and LB wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Research Scientific Ethics Committee of the Affiliated Zhongshan Hospital of Dalian University (Dalian, China) and written informed consent was obtained from all participants.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7‑34, 2019.
2. Li C, Zhang L, Meng G, Wang Q, Lv X, Zhang J and Li J: Circular RNAs: Pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non‑small cell lung cancer. J Cancer Res Clin Oncol 145: 2875‑2889, 2019.
3. Zhang J, Xu C, Gao Y, Wang Y, Ding Z, Zhang Y, Shen W, Zheng Y and Wan Y: A novel long non‑coding RNA, MSTRG.51053.2 regulates cisplatin resistance by sponging the miR‑432‑5p in non‑small cell lung cancer cells. Front Oncol 10: 215‑215, 2020.
4. Sun M, He L, Fan Z, Tang R and Du J: Effective treatment of drug‑resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. Biomaterials 257: 120252, 2020.
5. Schmidtova S, Kalavska K and Kucerova L: Molecular mechanisms of cisplatin chemoresistance and its circumventing in testicular germ cell tumors. Curr Oncol Rep 20: 88, 2018.
6. Wang Y, Mo Y, Gong Z, Yang X, Yang M, Zhang S, Xiong F, Xiang B, Zhou M, Liao Q, et al: Circular RNAs: Pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non‑small cell lung cancer. J Cancer Res Clin Oncol 145: 2875‑2889, 2019.
7. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495: 333‑338, 2013.
8. Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu M, Dai X, Zhou H, Zhu J, Zhang H, et al: Circular RNA circSATB2 promotes progression of non‑small cell lung cancer cells. Mol Cancer 19: 101‑101, 2020.
9. Wang C, Tan S, Li J, Liu WR, Peng Y and Li W: Circular RNAs in lung cancer - Biogenesis, function and clinical implication. Cancer Lett 492: 106‑115, 2020.
10. Wang L, Zhao L and Wang Y: Circular RNA circ_0020123 promotes non‑small cell lung cancer progression by sponging miR‑590‑5p to regulate THBS2. Cancer Cell Int 20: 387, 2020.
11. Dong Y, Xu T, Zhong S, Wang B, Zhang H, Wang X, Wang P, Li G and Yang S: Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci 239: 116984, 2019.

12. Wu Z, Gong Q, Yu Y, Zhu J and Li W: Knockdown of circ-ABCB10 promotes sensitivity of lung cancer cells to cisplatin via miR-556-3p/AK4 axis. BMC Pulm Med 20: 10, 2020.

13. Zhang Y, Zhao H and Zang L: Identification of the tumor suppressive function of circular RNA FOXO3 in non small cell lung cancer through sponging miR 155. Mol Med Rep 17: 7692-7700, 2018.

14. Smolle E, Leko P, Stacher-Priehse E, Breic L, EI-Heleibi A, Hofmann L, Quehenberger F, Hrzenjak A, Popper HH, Olschewski H, et al: Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer. Mol Oncol 14: 2853-2867, 2020.

15. Haque MM and Desai KV: Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne) 10: 573, 2019.

16. Xiong Z, Fu Z, Shi J, Jiang X and Wan H: Hira1 Down-regulation induces cisplatin resistance in colon cancer by increasing XIAP and Activating PI3K/Akt pathway. Ann Clin Lab Sci 47: 264-270, 2017.

17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

18. Yin D, Hua L, Wang J, Liu Y and Li X: Long non-coding RNA DUXAP8 facilitates cell viability, migration, and glycolysis in non-small-cell lung cancer by regulating HK2 and LDHA by inhibition of miR-409-3p. Oncotargets Ther 13: 7111-7123, 2020.

19. Wang L, Tong X, Zhou Z, Wang S, Lei Z, Zhang T, Liu Z, Zeng Y, Li C, Zhao J, et al: Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer. Mol Cancer 17: 140, 2018.

20. Guo C, Wang H, Jiang H, Qiao L and Wang X: Circ_0011292 enhances paclitaxel resistance in non-small cell lung cancer by regulating miR-379-5p/TRIM65 axis. Cancer Biother Radiopharm: Aug 20, 2020 (Epub ahead of print).

21. Lu M, Xiong H, Xia ZK, Liu B, Wu F, Zhang HX, Hu CH and Liu P: circRACGAP1 promotes non small cell lung cancer proliferation by regulating miR 144 5p/CDKL1 signaling pathway. Cancer Gene Ther 28: 197-211, 2021.

22. Song L, Cui Z and Guo X: Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines. Acta Biochim Biophys Sin (Shanghai) 52: 944-953, 2020.

23. Zhao Y, Zheng R, Chen J and Ning D: circRNA CDR1as/miR-6-4/AHOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell Int 20: 289, 2020.

24. Akins NS, Nielson TC and Le HV: Inhibition of glycolysis and glutaminolysis: An emerging drug discovery approach to combat cancer. Curr Top Med Chem 18: 494-504, 2018.

25. Guo J, Su Y and Zhang M: Circ_0000140 restrains the proliferation, metastasis and glycolysis metabolism of oral squamous cell carcinoma through upregulating CDC73 via sponging miR-182-5p. Cancer Cell Int 20: 407, 2020.

26. Xu Y, Jiang T, Wu C and Zhang Y: circAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity. Biotechnol Lett 42: 1123-1135, 2020.

27. Zhou C, Zhao X and Duan S: The role of miR 543 in human cancerous and noncancerous diseases. J Cell Physiol 236: 15-26, 2021.

28. Hu J, Chen Y, Li X, Miao H, Li R, Chen D and Wen Z: THUMPD3-A51 is correlated with non-small cell lung cancer and regulates self-renewal through miR-543 and ONECUT1, Oncotargets Ther 12: 9849-9860, 2019.

29. Wang D, Cai L, Tian X and Li W: miR-543 promotes tumorigenesis and angiogenesis in non-small cell lung cancer via modulating metastasis associated protein 1. Mol Med 26: 44, 2020.

30. Liu G, Zhou J and Dong M: Down regulation of miR 543 expression increases the sensitivity of colorectal cancer cells to 5 Fluorouracil through the PTEN/PI3K/AKT pathway. Biosci Rep 39: BSR20190249, 2019.

31. Ma Z, Gu G, Pan W and Chen X: LncRNA PCAT6 accelerates the progression and chemoresistance of cervical cancer through up-regulating ZEB1 by sponging miR-543. Oncotargets Ther 13: 1159-1170, 2020.